

# Gabriele Fragasso

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8149592/publications.pdf>

Version: 2024-02-01

78  
papers

2,996  
citations

218677

26  
h-index

161849

54  
g-index

82  
all docs

82  
docs citations

82  
times ranked

3329  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vasostatin-1 as a potential novel circulating biomarker in patients with chronic systolic heart failure: A pilot study. <i>Clinica Chimica Acta</i> , 2022, 526, 49-54.	1.1	0
2	Editorial Commentary: Drug dosing optimization in heart failure: Need of a multidimensional approach (and skilled heart failure specialists). <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 117-118.	4.9	2
3	<scp>Heart Failure Association</scp> of the <scp>European Society of Cardiology</scp> update on sodium-glucose co-transporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1984-1986.	7.1	66
4	Long-term clinical effects of recanalization of chronic coronary total occlusions in patients with left ventricular systolic dysfunction. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 831-838.	1.7	2
5	Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1495-1503.	7.1	100
6	Metabolic effects of cardiovascular drugs. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 176-187.	4.9	9
7	Risk of cardiac and sudden death with and without revascularisation of a coronary chronic total occlusion. <i>Heart</i> , 2019, 105, 1096-1102.	2.9	19
8	Real-Life Indications to Sacubitril/Valsartan Treatment in Patients With Chronic Systolic Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 73, 301-306.	1.9	4
9	Editorial commentary: Pathophysiological effects of proton pump inhibitors in cardiac patients: Time for a critical reappraisal. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 361-362.	4.9	1
10	Validation of a new score for outcome prediction in patients with heart failure with reduced ejection fraction. <i>Minerva Cardioangiologica</i> , 2019, 67, 191-199.	1.2	4
11	Age-related reduction of myocardial metabolic efficiency: Is it time to routinely measure myocardial metabolism to monitor cardiac health?. <i>Heart</i> , 2018, 104, 88-89.	2.9	2
12	Extracorporeal myocardial shockwave therapy; a precious blast for refractory angina patients. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 263-267.	0.8	10
13	Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 351-356.	1.5	4
14	Two-year cardiac mortality after MitraClip treatment of functional mitral regurgitation in ischemic and non-ischemic dilated cardiomyopathy. <i>International Journal of Cardiology</i> , 2018, 269, 33-39.	1.7	42
15	Pathophysiological mechanisms should be taken into account and guide the treatment of essential arterial hypertension. <i>Indian Heart Journal</i> , 2017, 69, 417.	0.5	0
16	Early left atrial tissue features in patients with chronic mitral regurgitation and sinus rhythm: Alterations of not remodeled left atria. <i>International Journal of Cardiology</i> , 2016, 219, 433-438.	1.7	7
17	Pathophysiological Mechanisms and Correlates of Therapeutic Pharmacological Interventions in Essential Arterial Hypertension. <i>Advances in Experimental Medicine and Biology</i> , 2016, 956, 37-59.	1.6	8
18	Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. <i>International Journal of Cardiology</i> , 2016, 203, 909-915.	1.7	67

#	ARTICLE	IF	CITATIONS
19	Deranged cardiac metabolism and the pathogenesis of heart failure. <i>Cardiac Failure Review</i> , 2016, 2, 8.	3.0	19
20	Oral direct thrombin inhibition: a double-edged sword?. <i>Heart, Lung and Vessels</i> , 2015, 7, 191-7.	0.4	2
21	Prognostic role of stress/rest myocardial perfusion scintigraphy in patients with cardiac syndrome x. <i>International Journal of Cardiology</i> , 2014, 173, 467-471.	1.7	10
22	Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: Results from an international multicentre retrospective cohort study. <i>International Journal of Cardiology</i> , 2013, 163, 320-325.	1.7	77
23	Feasibility and safety of transcatheter closure of atrial septal defects with deficient posterior rim. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 1180-1187.	1.7	27
24	Beneficial effects of beta-blockers on left ventricular function and cellular energy reserve in patients with heart failure. <i>Fundamental and Clinical Pharmacology</i> , 2013, 27, 455-464.	1.9	27
25	Erectile dysfunction in heart failure patients: a critical reappraisal. <i>Andrology</i> , 2013, 1, 177-191.	3.5	23
26	Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 49-56.	1.5	6
27	Improved survival in patients with chronic mild/moderate systolic heart failure followed up in a specialist clinic. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 57-65.	1.5	1
28	Myocardial 99m-Tc tetrofosmin reverse redistribution as a possible marker of tissue at risk. <i>Anatolian Journal of Cardiology</i> , 2012, 13, 184-6.	0.4	0
29	Pathophysiologic therapeutic targets in hypertension: a cardiological point of view. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 179-193.	3.4	9
30	Tumor Necrosis Factor $\alpha$ As a Master Regulator of Inflammation in Erdheim-Chester Disease: Rationale for the Treatment of Patients With Infliximab. <i>Journal of Clinical Oncology</i> , 2012, 30, e286-e290.	1.6	79
31	Resting cardiac energy metabolism is inversely associated with heart rate in healthy young adult men. <i>American Heart Journal</i> , 2011, 162, 136-141.	2.7	12
32	A high carbohydrate meal yields a lower ischemic threshold than a high fat meal in patients with stable coronary disease. <i>International Journal of Cardiology</i> , 2011, 147, 209-213.	1.7	3
33	Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure. <i>Heart</i> , 2011, 97, 1495-1500.	2.9	60
34	Comparison of Exercise Electrocardiography, Technetium-99m Sestamibi Single Photon Emission Computed Tomography, and Dobutamine and Dipyridamole Echocardiography for Detection of Coronary Artery Disease in Hypertensive Women. <i>American Journal of Cardiology</i> , 2010, 105, 1254-1260.	1.6	9
35	Role of Metabolic Modulation in the Management of Chronic Ischemic Heart Disease. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S3159.	0.4	0
36	Beneficial Electrophysiological Effects of Trimetazidine in Patients With Posts ischemic Chronic Heart Failure. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2010, 15, 24-30.	2.0	28

#	ARTICLE	IF	CITATIONS
37	Prognosis of mild/moderate chronic systolic heart failure. <i>International Journal of Cardiology</i> , 2010, 145, 584-586.	1.7	2
38	Effects of Metabolic Approach in Diabetic Patients with Coronary Artery Disease. <i>Current Pharmaceutical Design</i> , 2009, 15, 857-862.	1.9	19
39	Cardiotoxicity after low-dose chloroquine antimalarial therapy. <i>Heart and Vessels</i> , 2009, 24, 385-387.	1.2	18
40	Coronary slow-flow causing transient myocardial hypoperfusion in patients with cardiac syndrome X: Long-term clinical and functional prognosis. <i>International Journal of Cardiology</i> , 2009, 137, 137-144.	1.7	52
41	Different Metabolic Effects of Selective and Nonselective Beta-Blockers Rather Than Mere Heart Rate Reduction May Be the Mechanisms by Which Beta-Blockade Prevents Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2009, 53, 2105.	2.8	4
42	Safety and efficacy of doxazosin as an 'add-on' antihypertensive therapy in mild to moderate heart failure patients. <i>Acta Cardiologica</i> , 2009, 64, 485-491.	0.9	8
43	Heart Rate Reduction Is Probably Not the Main Beneficial Mechanism by Which Beta Blockade Improves Outcome in Patients With Systolic Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2008, 102, 506-507.	1.6	6
44	Metabolic Therapy of Heart Failure. <i>Current Pharmaceutical Design</i> , 2008, 14, 2582-2591.	1.9	18
45	Differential Long-term Effects of Carvedilol on Proinflammatory and Antiinflammatory Cytokines, Asymmetric Dimethylarginine, and Left Ventricular Function in Patients With Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2008, 52, 49-54.	1.9	21
46	Letter by Fragasso et al Regarding Article by Tuunanen et al, "Free Fatty Acid Depletion Acutely Decreases Cardiac Work and Efficiency in Cardiomyopathic Heart Failure" <i>Circulation</i> , 2007, 115, e546; author reply e547.	1.6	1
47	Modulation of Fatty Acids Oxidation in Heart Failure by Selective Pharmacological Inhibition of 3-Ketoacyl Coenzyme-A Thiolase. <i>Current Clinical Pharmacology</i> , 2007, 2, 190-196.	0.6	21
48	Validation of Remote Cardiopulmonary Examination in Patients With Heart Failure With a Videophone-Based System. <i>Journal of Cardiac Failure</i> , 2007, 13, 281-286.	1.7	19
49	Inhibition of free fatty acids metabolism as a therapeutic target in patients with heart failure. <i>International Journal of Clinical Practice</i> , 2007, 61, 603-610.	1.7	17
50	New directions in the treatment of heart failure: Targeting free fatty acid oxidation. <i>Current Heart Failure Reports</i> , 2007, 4, 236-242.	3.3	3
51	Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 290, E54-E59.	3.5	67
52	The anti-ischemic effect of trimetazidine in patients with postprandial myocardial ischemia is unrelated to meal composition. <i>American Heart Journal</i> , 2006, 151, 1238.e1-1238.e8.	2.7	8
53	Assessment of Stress-induced Pulmonary Interstitial Edema by Chest Ultrasound During Exercise Echocardiography and its Correlation with Left Ventricular Function. <i>Journal of the American Society of Echocardiography</i> , 2006, 19, 457-463.	2.8	118
54	A Randomized Clinical Trial of Trimetazidine, a Partial Free Fatty Acid Oxidation Inhibitor, in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2006, 48, 992-998.	2.8	225

#	ARTICLE	IF	CITATIONS
55	Elderly manifestation of non-compaction of the ventricular myocardium. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 714-716.	1.5	7
56	Metabolic Therapy for Patients with Diabetes Mellitus and Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2006, 98, 14-18.	1.6	225
57	Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. <i>European Heart Journal</i> , 2006, 27, 942-948.	2.2	210
58	Insulin resistance and endothelial function are improved after folate and vitamin B12 therapy in patients with metabolic syndrome: relationship between homocysteine levels and hyperinsulinemia. <i>European Journal of Endocrinology</i> , 2004, 151, 483-489.	3.7	138
59	Nitric-Oxide Mediated Effects of Transdermal Capsaicin Patches on the Ischemic Threshold in Patients with Stable Coronary Disease. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, 340-347.	1.9	20
60	Effect of oral L-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise tests, and normal coronary arteries. <i>American Journal of Cardiology</i> , 2004, 93, 933-935.	1.6	114
61	Early detection by the Tei index of carvedilol-induced improved left ventricular function in patients with heart failure. <i>American Journal of Cardiology</i> , 2004, 94, 1456-1459.	1.6	18
62	Validation of heart and lung teleauscultation on an Internet-Based system. <i>American Journal of Cardiology</i> , 2003, 92, 1138-1139.	1.6	5
63	Association of Insulin Resistance, Hyperleptinemia, and Impaired Nitric Oxide Release With In-Stent Restenosis in Patients Undergoing Coronary Stenting. <i>Circulation</i> , 2003, 108, 2074-2081.	1.6	175
64	Acute Intravenous L-Arginine Infusion Decreases Endothelin-1 Levels and Improves Endothelial Function in Patients With Angina Pectoris and Normal Coronary Arteriograms. <i>Circulation</i> , 2003, 107, 429-436.	1.6	105
65	Acute effects of heparin administration on the ischemic threshold of patients with coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2002, 39, 413-419.	2.8	25
66	Magnetic resonance image (MRI) of an acquired aorto-pulmonary fistula, associated with cerebral and paradoxical embolism. <i>International Journal of Cardiology</i> , 2002, 83, 85-86.	1.7	4
67	Time course and determinants of left ventricular function recovery after primary angioplasty in patients with acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2001, 38, 464-471.	2.8	52
68	Influence of treatment delay on long-term left ventricular function in patients with acute myocardial infarction successfully treated with primary angioplasty. <i>American Heart Journal</i> , 2001, 141, 603-609.	2.7	15
69	Enoximone Echocardiography for Predicting Recovery of Left Ventricular Dysfunction After Revascularization. <i>Circulation</i> , 2000, 101, 1255-1260.	1.6	25
70	Comparison of stress/rest myocardial perfusion tomography, dipyridamole and dobutamine stress echocardiography for the detection of coronary disease in hypertensive patients with chest pain and positive exercise test. <i>Journal of the American College of Cardiology</i> , 1999, 34, 441-447.	2.8	128
71	Endothelial and metabolic characteristics of patients with angina and angiographically normal coronary arteries. <i>Journal of the American College of Cardiology</i> , 1999, 34, 1452-1460.	2.8	61
72	Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. <i>American Journal of Cardiology</i> , 1998, 82, 898-901.	1.6	84

#	ARTICLE	IF	CITATIONS
73	Septal Panniculitis Induced by Atenolol. <i>Angiology</i> , 1998, 49, 499-502.	1.8	5
74	Effect of Atenolol on QT Interval and Dispersion in Patients With Syndrome X. <i>American Journal of Cardiology</i> , 1997, 80, 789-790.	1.6	33
75	Specificity and sensitivity of exercise-induced st segment elevation for detection of residual viability: Comparison with fluorodeoxyglucose and positron emission tomography. <i>Journal of the American College of Cardiology</i> , 1995, 25, 1032-1038.	2.8	86
76	Antiischemic Effects of Intravenous Diazepam in Patients with Coronary Artery Disease. <i>Journal of Cardiovascular Pharmacology</i> , 1994, 24, 55-58.	1.9	20
77	Symptom-limited exercise testing causes sustained diastolic dysfunction in patients with coronary disease and low effort tolerance. <i>Journal of the American College of Cardiology</i> , 1991, 17, 1251-1255.	2.8	44
78	Usefulness of holter monitoring to improve the sensitivity of exercise testing in determining the degree of myocardial revascularization after coronary artery bypass grafting for stable angina pectoris. <i>American Journal of Cardiology</i> , 1987, 60, 40-43.	1.6	29